Asset Management Company
VC Fund
Palo Alto, United States
Asset Management Company is a VC fund in Palo Alto focused on Health Care and Biotechnology. For over 45 years, the goal of Asset Management Company has been to partner with visionary entrepreneurs and to help create valuable new companies and important new industries by investing capital in exciting, new, technology-based opportunities. “We have observed the ups and downs of venture capital and the fads and failures in the Valley. So wealways took the long view,” says Pitch Johnson, founding partner. As of 2012, Asset Management Company has become a family office. Our focus now is managing the Johnson family investments and supporting a variety of not-for-profit organizations through corporate philanthropy and a family foundation.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Asset Management Company invests in
Stages Asset Management Company invests in
Countries Asset Management Company invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Franklin Johnson
|
|||
Investment Focus
Industry
- Health Care 5 (36%)
- Biotechnology 4 (29%)
- Pharmaceutical 3 (21%)
- Mobile 2 (14%)
- Medical 2 (14%)
Stage
- Series B 3 (21%)
- Funding Round 3 (21%)
- Series A 2 (14%)
- Series C 2 (14%)
- Series E 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Franklin Johnson
Founder & Partner
|
Founder & Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
InteKrin
|
InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatmentalternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity. | $2.3M / Jun 14, 2010 | |
Biomimedica
|
Biomimedica is a medical device company that is pioneering new approaches to joint repair through its proprietary, synthetic cartilage technology. It was founded in 2007 and is based in South San Francisco, California, United States. | $250K / Debt Financing / Apr 12, 2010 | |
Chimerix
|
Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA(dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs. | $16.1M / Series E / Aug 10, 2009 | |
BiPar Sciences
|
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.BiPar has raised around $60 million in VC funding, from firms like On April 15th, 2009, French drug maker | $20M / Series C / Jan 12, 2009 | |
|
InteKrin
|
InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatmentalternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity. | $18.5M / Series C / Aug 04, 2008 | |
Sonoma Orthopedics
|
Sonoma Orthopedic Products designs, develops, and delivers proprietary orthopedic implants for physicians to address problematic fractures. The WaviBodyâ„¢ technology platform allows for quick, minimally invasive surgical solutions for active patients. Direct to Bone...Back To Life. | $10M / Series B / May 21, 2007 | |
|
Sonoma Orthopedics
|
Sonoma Orthopedic Products designs, develops, and delivers proprietary orthopedic implants for physicians to address problematic fractures. The WaviBodyâ„¢ technology platform allows for quick, minimally invasive surgical solutions for active patients. Direct to Bone...Back To Life. | $3M / Series A / Apr 01, 2007 | |
|
BiPar Sciences
|
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.BiPar has raised around $60 million in VC funding, from firms like On April 15th, 2009, French drug maker | $35M / Series B / Feb 26, 2007 | |
|
BiPar Sciences
|
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.BiPar has raised around $60 million in VC funding, from firms like On April 15th, 2009, French drug maker | $13M / Series A / Dec 20, 2004 | |
Proteus Digital Health
|
Proteus Digital Health® is creating a new category of pharmaceuticals: Digital Medicines. Digital Medicines includes drugs that communicate when they’ve been taken, wearable sensors that capture physiologic response, applications that support patient self-care and physician decision making and data analytics to serve the needs of doctors and healthsystems. The goal of Digital Medicines is to empower patients and their families, enable physicians and health systems to more effectively manage risk and ensure that outcomes are reliably achieved. | $6.3M / Series B / Jun 23, 2004 | |
| See all 14 investments → | |||
Co-Investors
Asset Management Ventures (AMV)
7 deals together
Canaan Partners
4 deals together
PolyTechnos Venture Partners
3 deals together
Quantum Technology Partners
3 deals together
Vulcan Capital
3 deals together
Domain Associates
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Asset Management Company invest in?
Asset Management Company invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Funding Round stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Asset Management Company?
Public channels for Asset Management Company include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Asset Management Company?
The team at Asset Management Company includes Franklin Johnson (Founder & Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
